A Swedish and a UK company have joined forces to develop treatments for cancer.
Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Swiss firm ADC Therapeutics Sarl (ADCT) have signed agreements to develop Antibody Drug Conjugates (ADCs).
They will use CRT antibodies and peptides to build these oncology drugs, with the role of the antibody component being to selectively target the cancer cells with tumour-destroying chemicals.
ADCT will initially fund preclinical studies for the new treatments in laboratories at Queen Mary, University of London, and King's College London.
Dr Chris Martin, ADCT's collaboration manager and chief executive officer of Spirogen Limited, said: "We are very excited to see our potent PBD-based warheads combined with CRT’s leading tumour-targeting antibodies and peptides."
Earlier this month, Cancer Research UK awarded grants to seven of the UK's up and coming new cancer researchers.
The grants are designed to help the scientists on their way towards becoming tomorrow's cancer research leaders.